To honor the World TB Day on Mar 24, 2015, California-based molecular diagnostics provider Cepheid CPHD along with the National Health Laboratory Services (NHLS) of South Africa, recently announced ...

SUNNYVALE, Calif., April 3, 2024 /PRNewswire/ -- Cepheid today announced that Xpert® HIV-1 Qual XC has been awarded World Health Organization (WHO) prequalification. Inclusion on the prequalification ...

In an attempt to strengthen its foothold in the virology market, molecular diagnostics corporation Cepheid (CPHD), together with the not-for-profit organization – Foundation for Innovative New ...

First and Only Trichomonas NAAT Test with Male Urine Claims Cleared for Use in United States Following initial clearance of Xpert TV for three types of female specimens in October of 2015, the latest ...

CepheidCPHD recently received an approval for its Xpert TV assay from the U.S. FDA. Notably, Xpert TV is a urine-based test that uses the Nucleic Acid Amplification Testing (NAAT) procedure for ...

SUNNYVALE, Calif., Feb. 14, 2023 /PRNewswire/ -- Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration for Xpert Mpox, which runs on ...

The FDA has approved Cepheid Xpert C. difficile/Epi assay for the detection of the toxin B gene associated with Clostridium difficile infection. The Cepheid Xpert C. difficile/Epi assay determines if ...

Redesigned test introduces two new targets to improve coverage and sensitivity for Group B Streptococcus intrapartum testing for pregnant females Group B Streptococcus (GBS) is the leading cause of ...

Cepheid has announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert™ MRSA test, which runs on the GeneXpert® System, for the detection of ...

The European LeukemiaNet recommends quantitative molecular assessment of NPM1 by qPCR as part of minimal residual disease (MRD) monitoring of patients with NPM1-mutated AML 1. Acute myeloid leukemia ...